She notes the FDA approved a change to Zepbound's labeling in October 2024, adding context to a study now circulating online.
Recap by typeshit. Post by Jen Can NuSH on X.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Jen Can NuSH flags two new trials without placebo arms, one for the GLP-1/glucagon drug survodutide and one for Pfizer's GLP-1 berobenatide.
Designers are making pieces that adjust as bodies change size, so people losing or regaining weight don't need a whole new wardrobe.
Loading…